PharmAla Biotech Holdings Inc. (MDXXF) has made a major stride in its mission to advance MDMA-based research. The company has signed an agreement to supply its LaNeo MDMA for a clinical trial at Harvard’s McLean Hospital, a world-leading institution in neuroscience and psychiatric research. This partnership marks a significant milestone for PharmAla as it continues to expand its presence in the growing field of MDMA-assisted therapy.
The company’s CEO, Nicholas Kadysh, expressed the company’s enthusiasm for the collaboration, emphasizing the growing interest from key research organizations in MDMA-based therapies. PharmAla’s commitment to delivering high-quality MDMA for clinical trials is evident in this latest agreement.
This development comes hot on the heels of another major contract secured by PharmAla. Less than a month ago, the company was chosen as a supplier of MDMA for a clinical trial at Johns Hopkins Medicine, another prestigious institution.
PharmAla’s dedication to expanding its reach goes beyond the U.S. borders. The company is set to attend the CPHI conference in Milan from October 7-11, where they will be actively seeking potential European distribution partners. Dr. Shane Morris, PharmAla’s COO, highlighted the company’s ongoing efforts to build a robust distribution network in Europe.
“Over the past few months, PharmAla has been in discussion with a number of potential distribution partners in the European market,” said Dr. Morris. “We’re looking forward to the opportunity to meet with them, in-person, to continue those fruitful discussions.”
PharmAla’s success in securing agreements with top research institutions and its proactive approach to establishing international partnerships are a testament to its commitment to advancing MDMA-based research and making it more accessible worldwide. The company’s involvement in these crucial clinical trials could lead to groundbreaking discoveries and advancements in the treatment of various mental health conditions.
